Thryv Therapeutics Inc.
thryvtrx.com
Actively hiring
Medical AI
Precision Medicine
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Lumira Ventures
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 15, 2023
Certified Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Present… · krqe.com
Nov 29, 2022
Board appointment Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors · Nasdaq
Backed byfrom the funds' portfolios and accelerator catalogs
Lumira Ventures Similar startupsby what they do, their industry and backers
Q2 Metals is a Canadian mineral exploration company focused on progressing the Cisco Lithium Project in James Bay, Quebec, Canada.
Top of page We are privately owned Yield Systems is a privately owned Finnish companylocated in Helsinki, Finland. Our Mission Yield…
ABOUT US IteriaBiopharma is a privately owned Spanish biotech founded in 2024 by a team of experienced entrepreneurs in drug discovery and…
AI Research Research Overview Causality Representation Learning Survival Analysis Ataraxis Breast Ataraxis Breast Overview Recurrence Risk…
Mindpeak transforms tissue into high-dimensional data, enabling the discovery of AI-driven biomarkers that guide targeted therapies and…
Panakeia is a London medical technology company founded in 2018 that predicts molecular tumour profiles from routine pathology slides. Its…
News
Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure
Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the publication of its new study in JACC:
Read more
Report
Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain
Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, today announced that it has entered into an exclusive, worldwide, royalty-bearing patent and know-how license agreement with the Spanish Nat
Read more
Report
Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
Read more
Report
Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited and acquired cardiometabolic diseases, today announced its participation in three upcoming prominent in
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Montreal
Canada
Regional office
Location: 999 Blvd. De Maisonneuve West, Suite 1250, Montreal, Quebec H3A 3L4 Canada
Location: 999 Blvd. De Maisonneuve West, Suite 1250, Montreal, Quebec H3A 3L4 Canada
Westmount
Canada
Regional office
999 Blvd. De Maisonneuve West, Suite 1250 Westmount, QC, Canada